Rx Product News (September 2017)

Gilead Sciences

INDICATION: The FDA approved Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) to treat chronic hepatitis C virus infection genotypes 1-6 in patients without cirrhosis or with mild cirrhosis.

DOSAGE FORM: Tablets: 400-mg sofosbuvir, 100- mg velpatasvir, and 100-mg voxilaprevir

FOR MORE INFORMATION: gilead.com

IDHIFAMARKETED BY: Celgene

INDICATION: The FDA has approved Idhifa (enasidenib) to treat adult patients with relapsed or refractory acute myeloid leukemia who have an isocitrate dehydrogenase- 2 gene mutation.

DOSAGE FORM: Tablets: 50 mg or 100 mg

FOR MORE INFORMATION: Celgene.com

TREMFYAMARKETED BY: Janssen Biotech

INDICATION: The FDA has approved Tremfya (guselkumab) to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

DOSAGE FORM: Injection: 100 mg/mL

FOR MORE INFORMATION: janssen.com

BLINCYTOMARKETED BY: Amgen

INDICATION: The FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) to include overall survival data from the phase 3 TOWER study, converting Blincyto’s accelerated approval to a full approval. The approval expands the indication of Blincyto to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.

DOSAGE FORM: Injection: 35 mcg

FOR MORE INFORMATION: amgen.com